Business
At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (ALZHEMED(TM))
At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (ALZHEMED(TM)).
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nWASHINGTON, DC, June 11 /CNW Telbec/ - Paul S. Aisen, M.D., Professor of\nNeurology and Medicine at Georgetown University Medical Center, and principal\ninvestigator in the United States of Neurochem Inc.'s North American Phase III\nclinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on\nNeurochem's investigational product candidate for the treatment of Alzheimer's\ndisease (AD). The presentation by Dr. Aisen will take place at the\nIntervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at\nthe Alzheimer's Association International Conference on Prevention of Dementia\nin Washington, DC. In his presentation entitled, A Phase III Study of the\nEfficacy, Safety and Disease Modification Effect of Tramiprosate in\nMild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III\nclinical trial and provide an update.\n\n\nNeurochem announced in April 2007 that an adjustment to the initial\nstatistical model, as set out in the statistical plan, would be necessary to\nprovide accurate results. The procedure to arrive at a reliable model involves\na detailed analysis of potential confounding factors, and Dr. Aisen will\npresent on the progress to date. In addition, Dr. Aisen will provide an update\non the progress in the analysis of the Phase III clinical trial primary\nendpoint data. Some preliminary descriptive data shows numerical differences\nin favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and\nalso shows differences between groups on the primary disease modification\nendpoint as measured by magnetic resonance imaging (MRI). However, work\nregarding the adjustment of the statistical model is ongoing and, therefore\nresults of the Phase III clinical trial cannot be derived from the preliminary\ndata nor can statistical significance be assigned at this time. Accordingly,\nno predictions or conclusions can yet be made regarding the outcome of the\nPhase III study.\n\n\nNeurochem continues to expect to announce the top-line results of the\ntrial during the second quarter of this year, although they may not be\navailable within this timeframe. The actual timing of the release of these\ntop-line results depends on completing the adjustments to the initial\nstatistical model.\n\n\nAlzheimer's Association News Briefing\n\n\nThe Alzheimer's Association has i...